Sverige - svenska - Läkemedelsverket (Medical Products Agency)

glenmark arzneimittel gmbh - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 100 mg - sitagliptinhydrokloridmonohydrat 108,95 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

glenmark arzneimittel gmbh - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 25 mg - sitagliptinhydrokloridmonohydrat 27,238 mg aktiv substans; laktosmonohydrat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 100 mg - sitagliptinhydrokloridmonohydrat 108,95 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 25 mg - sitagliptinhydrokloridmonohydrat 27,238 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medical valley invest ab - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 25 mg - laktosmonohydrat hjälpämne; sitagliptinhydrokloridmonohydrat 27,238 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg - para-orange hjälpämne; natriumbensoat hjälpämne; sitagliptinhydrokloridmonohydrat 54,475 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laurus generics gmbh - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 100 mg - sitagliptinhydrokloridmonohydrat 113,38 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laurus generics gmbh - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 25 mg - sitagliptinhydrokloridmonohydrat 28,345 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laurus generics gmbh - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg - sitagliptinhydrokloridmonohydrat 56,69 mg aktiv substans